Organon & Co. OGN recently announced findings from a pooled sub-analysis of its Phase 3 ADORING 1 and ADORING 2 pivotal trials assessing VTAMA (tapinarof) cream, 1%, in pediatric patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results